Research Summary

Dr. Francis Yao is a gastroenterologist who serves as medical director of the UCSF Liver Transplant Program. He also directs the UCSF Liver Transplant Outreach and Community Liaison Program.

In his research, Yao is interested in liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include hepatitis B infection and outcomes for patients undergoing liver transplantation.

Selected Publications

  1. Giard JM, Dodge JL, Yao FY, Mehta N. Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation. Liver Transpl. 2022 Jul 09.  View on PubMed
  2. Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N. National experience with living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2022 07; 28(7):1144-1157.  View on PubMed
  3. Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma. Liver Transpl. 2022 05; 28(5):763-773.  View on PubMed
  4. Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma. Liver Transpl. 2022 03; 28(3):376-385.  View on PubMed
  5. Yao F. Review of Liver Transplantation in Patients With Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y). 2021 Nov; 17(11):536-538.  View on PubMed
  6. Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. Sex-based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation. 2021 11 01; 105(11):2420-2426.  View on PubMed
  7. Mehta N, Yao FY. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolization: Pipe Dream or Reality? Liver Transpl. 2021 12; 27(12):1706-1708.  View on PubMed
  8. Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021 11; 161(5):1502-1512.  View on PubMed
  9. Harding-Theobald E, Yao FYK, Mehta N. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl. 2021 06; 27(6):818-829.  View on PubMed
  10. Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol. 2021 05; 216(5):1283-1290.  View on PubMed
  11. Bond AR, Bainbridge E, Doernberg SB, Babik JM, Miller S, Khanafshar E, Henry T, David A, Russell M, Brandman D, Sherman CB, Yao F, Fung M. Disseminated Legionella micdadei infection in a liver transplant patient presenting as pulmonary nodules and a laryngeal lesion. Transpl Infect Dis. 2021 Jun; 23(3):e13563.  View on PubMed
  12. Kotwani P, Chan W, Yao F, Mehta N. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study. Clin Gastroenterol Hepatol. 2022 03; 20(3):701-703.e2.  View on PubMed
  13. Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis. 2021 05; 41(2):117-127.  View on PubMed
  14. Mehta N, Yao FY. Reply. Hepatology. 2020 12; 72(6):2243-2244.  View on PubMed
  15. Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol. 2021 04; 74(4):829-837.  View on PubMed
  16. Sherman C, Syed S, Gardner J, Yao FY. CON: Portal Vein Thrombosis Does Not Impact Liver Transplantation Outcomes. Clin Liver Dis (Hoboken). 2020 Oct; 16(4):132.  View on PubMed
  17. Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions. Transplantation. 2020 11; 104(11):2215-2220.  View on PubMed
  18. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology. 2020 11; 72(5):1654-1665.  View on PubMed
  19. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival. Transplantation. 2020 10; 104(10):2105-2112.  View on PubMed
  20. Weinfurtner K, Dodge JL, Yao FYK, Mehta N. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. Transplant Direct. 2020 Oct; 6(10):e605.  View on PubMed

Go to UCSF Profiles, powered by CTSI